SRPT
Sarepta Therapeutics
$15.89
+$0.21 (+1.34%)Jul 27, 2026
Key metrics
The numbers that frame SRPT today
- Market cap
- $1.68B
- P/E (TTM)
- 25.8
- EV / FCF
- 20.6
- Gross margin
- 62.9%
- EV / Sales
- 1.0
- ROIC
- 0.8%
- Div yield
- 0%
- Debt / equity
- 0.7
- 52wk Low
- $11.12
- 52wk High
- $25.32
Growth
Revenue and earnings trend for SRPT
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about SRPT
Is Sarepta Therapeutics a good buy?
Hold. Sarepta Therapeutics has strong quality, but weak momentum makes the setup mixed. Growth looks excellent, which supports the long-term business case. We think Sarepta Therapeutics is selling at a fair price.
What is the market capitalization of SRPT?
Sarepta Therapeutics's market capitalization is $1.68B.
What is the P/E ratio for SRPT stock?
Sarepta Therapeutics's current P/E ratio is 25.8.
What is the 52-week high for SRPT stock?
The 52-week high for Sarepta Therapeutics is $25.32. The current close of $15.89 is 37.2% below that high.
What is the 52-week low for SRPT stock?
The 52-week low for Sarepta Therapeutics is $11.12. The current close of $15.89 is 42.9% above that low.
Does SRPT stock pay dividends?
Sarepta Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for SRPT?
Sarepta Therapeutics's Debt / Equity ratio is 0.69.